Literature DB >> 12517859

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.

T Yamazumi1, M A Pfaller, S A Messer, A K Houston, L Boyken, R J Hollis, I Furuta, R N Jones.   

Abstract

Strains of Cryptococcus neoformans expressing heteroresistance to fluconazole have been described previously. The present study was conducted to investigate the prevalence of heteroresistance among clinical isolates of C. neoformans and to characterize the heteroresistant phenotypes. A total of 107 clinical isolates of C. neoformans for which the MICs of fluconazole ranged from 0.25 to 32 microg/ml were selected. The isolates were chosen to represent a broad geographic distribution. Of the 107 C. neoformans isolates tested, 4 grew on medium containing fluconazole at concentrations that were four to eight times higher than the MICs for each strain. A fifth isolate, for which the fluconazole MIC was 32 microg/ml, grew on agar with 64 microg of fluconazole per ml. These five isolates (4.7% of the total number) were confirmed to exhibit heteroresistant compositions by population analysis. The degree and frequency of resistance varied among the isolates. Stepwise selection by exposure to fluconazole resulted in subclones of all five strains for which the fluconazole MIC was >64 microg/ml. Subclones of three strains demonstrated a homogeneous population of resistant cells on medium containing 64 microg of fluconazole/ml. The resistance was sensitive to incubation temperature, that is, heteroresistance was demonstrable only at 30 degrees C by agar-based tests, and was reversible through serial transfers on fluconazole-free medium over a period of 8 days. These results suggest that the fluconazole-heteroresistant phenotype of C. neoformans exists in a significant proportion of clinical isolates and that fluconazole resistance can be developed by selection from heteroresistant clones and induction by exposure to fluconazole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517859      PMCID: PMC149577          DOI: 10.1128/JCM.41.1.267-272.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A Houston; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery.

Authors:  R A Hajjeh; M E Brandt; R W Pinner
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

3.  Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

Authors:  J Xu; C Onyewu; H J Yoell; R Y Ali; R J Vilgalys; T G Mitchell
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis.

Authors:  A Paugam; J Dupouy-Camet; P Blanche; J P Gangneux; C Tourte-Schaefer; D Sicard
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

5.  Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750.

Authors:  F Barchiesi; D Calabrese; D Sanglard; L Falconi Di Francesco; F Caselli; D Giannini; A Giacometti; S Gavaudan; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

6.  Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole.

Authors:  H Sanati; S A Messer; M Pfaller; M Witt; R Larsen; A Espinel-Ingroff; M Ghannoum
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 7.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

Authors:  W G Powderly; D Finkelstein; J Feinberg; P Frame; W He; C van der Horst; S L Koletar; M E Eyster; J Carey; H Waskin
Journal:  N Engl J Med       Date:  1995-03-16       Impact factor: 91.245

View more
  20 in total

Review 1.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

2.  Synthesis of a New Peptide-Coumarin Conjugate: A Potential Agent against Cryptococcosis.

Authors:  Soraya Z Ferreira; Hellem C Carneiro; Hugo A Lara; Rosemeire B Alves; Jarbas M Resende; Heloísa M Oliveira; Luciana M Silva; Daniel A Santos; Rossimiriam P Freitas
Journal:  ACS Med Chem Lett       Date:  2015-01-07       Impact factor: 4.345

3.  Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains.

Authors:  Jonathan Messika; Fatma Magdoud; Olivier Clermont; Dimitri Margetis; Stéphane Gaudry; Damien Roux; Catherine Branger; Didier Dreyfuss; Erick Denamur; Jean-Damien Ricard
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

Review 4.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

5.  A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae.

Authors:  Hansjürg Engel; Moana Mika; Dalia Denapaite; Regine Hakenbeck; Kathrin Mühlemann; Manfred Heller; Lucy J Hathaway; Markus Hilty
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

6.  Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Authors:  Edward Sionov; Hyeseung Lee; Yun C Chang; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

7.  Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment.

Authors:  Miwha Chang; Edward Sionov; Ami Khanal Lamichhane; Kyung J Kwon-Chung; Yun C Chang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

8.  Increase in resistance to fluconazole and itraconazole in Trichophyton rubrum clinical isolates by sequential passages in vitro under drug pressure.

Authors:  Anita Hryncewicz-Gwóźdź; Katarzyna Kalinowska; Ewa Plomer-Niezgoda; Jacek Bielecki; Tomasz Jagielski
Journal:  Mycopathologia       Date:  2013-04-18       Impact factor: 2.574

9.  Heteroresistance to penicillin in Streptococcus pneumoniae.

Authors:  Brigitte Morand; Kathrin Mühlemann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-17       Impact factor: 11.205

Review 10.  Efflux-mediated antifungal drug resistance.

Authors:  Richard D Cannon; Erwin Lamping; Ann R Holmes; Kyoko Niimi; Philippe V Baret; Mikhail V Keniya; Koichi Tanabe; Masakazu Niimi; Andre Goffeau; Brian C Monk
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.